Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

NCT04999800 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

UNKNOWN

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Anlotinib

Sponsor

Shi Yuankai